アフターアワーズ： 7.13 0.15 +2.15%

Recursion Pharmaceuticals Inc (RXRX)

Recursion Pharmaceuticals Inc (RXRX) 最新ニュース

Recursion Pharmaceuticals Inc (RXRX)

Recursion Pharmaceuticals Inc (RXRX) 最新ニュース

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SMAR, PANL, BALY, RXRX on Behalf of Shareholders - PR Newswire

Recursion Pharmaceuticals Inc(RXRX) Price Target Increased by 7.12% to 17.17 - MSN

Benjamin F. Edwards & Company Inc. Has $1.27 Million Stake in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) - MarketBeat

Recursion Pharmaceuticals (RXRX) Stock Dips While Market Gains: Key Facts - Yahoo Finance

Experts predict Recursion Pharmaceuticals Inc’s (RXRX) current quarter earnings growth rate - US Post News

Recursion Thinks AI Can Lower The High Failure Rate Of New Pharmaceutical Drugs - Forbes

How to Take Advantage of moves in (RXRX) - Stock Traders Daily

Recursion Pharmaceuticals director sells over $78k in company stock By Investing.com - Investing.com Australia

Is Recursion Pharmaceuticals Stock a Buy? - Yahoo Finance

Recursion Pharmaceuticals Inc [RXRX] Shares Fall Approximately -17.77% Over the Year - Knox Daily

Insider Sale: Director Blake Borgeson Sells Shares of Recursion Pharmaceuticals Inc (RXRX) - GuruFocus.com

Recursion Pharmaceuticals director sells over $78k in company stock By Investing.com - Investing.com South Africa

Blake Borgeson Sells 11,447 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Stock - MarketBeat

Recursion Pharmaceuticals director sells over $78k in company stock - Investing.com India

Recursion Pharmaceuticals director sells over $78k in company stock - Investing.com

Recursion Pharmaceuticals director sells over $78k in company stock By Investing.com - Investing.com UK

Angle celebrates agreement with Recursion Pharmaceuticals - Marketscreener.com

ANGLE signs pilot study agreement with AI-powered Recursion Pharmaceuticals - Proactive Investors USA

ANGLE plc Clinches Deal with Recursion Pharmaceuticals - TipRanks

ANGLE signs pilot study agreement with AI-powered Recursion Pharmaceuticals - Proactive Investors UK

Angle PLC Announces Agreement with Recursion Pharmaceuticals - AccessWire

Angle PLC Announces Agreement with Recursion Pharmaceuticals - StockTitan

Angle signs new agreement US biotech Recursion - Vox Markets

Recursion Pharmaceuticals (NASDAQ:RXRX) Trading 5.3% Higher - MarketBeat

Market Insights: Recursion Pharmaceuticals Inc (RXRX)’s Notable Gain of 1.65, Closing at 6.76 - The Dwinnex

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Shares Bought by Lingotto Investment Management LLP - MarketBeat

Arizona State Retirement System Has $358,000 Stock Holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) - Defense World

The Significance of Moving Averages in Recursion Pharmaceuticals Inc Inc. (RXRX) Price Performance - The InvestChronicle

Principal Financial Group Inc. Sells 362,215 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) - MarketBeat

Recursion Pharmaceuticals CFO Secora Michael sells shares worth $187,228 - Investing.com

Recursion Pharmaceuticals, Inc. (RXRX): A Very Important AI Stock According to BlackRock - Insider Monkey

Recursion Pharmaceuticals, Inc. (RXRX): A Very Important AI Stock According to BlackRock - Yahoo Finance

Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Gap Down to $6.32 - MarketBeat

Recursion: AI Is Only As Good As The Data (NASDAQ:RXRX) - Seeking Alpha

Bank of New York Mellon Corp Acquires 178,994 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) - MarketBeat

(RXRX) Proactive Strategies - Stock Traders Daily

Recursion Pharmaceuticals, Inc. (RXRX): Among the Worst ARK Stocks According to Short Sellers - Insider Monkey

10 Worst ARK Stocks To Buy According To Short Sellers - Insider Monkey

Recursion Pharmaceuticals CEO sells shares worth over $240,000 By Investing.com - Investing.com Australia

Recursion Pharmaceuticals CEO sells shares worth over $240,000 - Investing.com

Recursion Pharmaceuticals CEO sells shares worth over $240,000 - Investing.com India

Recursion Pharmaceuticals CEO sells shares worth over $240,000 By Investing.com - Investing.com Canada

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) CEO Sells $120,800.00 in Stock - MarketBeat

Recursion Pharmaceuticals CEO sells shares worth over $240,000 By Investing.com - Investing.com UK

Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Down 0.6% After Insider Selling - MarketBeat

Foundations Investment Advisors LLC Increases Position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) - MarketBeat

Recursion Stock Down Despite Meeting Goal in Brain Disease Study - MSN

Recursion Pharmaceuticals director sells $71,717 in stock - Investing.com

Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Up 1.1% - MarketBeat

Recursion Pharmaceuticals director sells $71,717 in stock - Investing.com India

Insider Selling: Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Director Sells 11,447 Shares of Stock - MarketBeat

Recursion Pharmaceuticals director sells $71,717 in stock By Investing.com - Investing.com UK

Commons Capital LLC Acquires New Stake in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) - MarketBeat

Recursion Pharmaceuticals Stock Is Sliding Tuesday: What's Going On? - MSN

Why Recursion Pharmaceuticals Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session - MSN

Recursion Stock: AI Hype Fizzles Amid Hard Clinical Truths (NASDAQ:RXRX) - Seeking Alpha

Cathie Wood's ARK sells CareDx, buys Recursion Pharmaceuticals stock By Investing.com - Investing.com Canada

Cathie Wood's ARK sells CareDx, buys Recursion Pharmaceuticals stock - Investing.com India

Cathie Wood's ARK sells CareDx, buys Recursion Pharmaceuticals stock - Investing.com

Cathie Wood's ARK sells CareDx, buys Recursion Pharmaceuticals stock By Investing.com - Investing.com UK

Recursion Pharmaceuticals (NASDAQ:RXRX) Given New $11.00 Price Target at Needham & Company LLC - MarketBeat

Recursion’s Ambitions: Developing 100+ Candidates, Joining with Exscientia - Genetic Engineering & Biotechnology News

Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Up 2.1% - MarketBeat

Recursion: Path Forward For REC-994 Remains Despite Mixed Response (NASDAQ:RXRX) - Seeking Alpha

Recursion Stock Down Despite Meeting Goal in Brain Disease Study - Zacks Investment Research

Recursion Stock Down Despite Meeting Goal in Brain Disease Study - Yahoo Finance

Decoding 6 Analyst Evaluations For Recursion Pharmaceuticals - Benzinga

AI-based Noetik closes on an oversubscribed $40M series A - BioWorld Online

Recursion Pharmaceuticals executive sells shares worth over $45,000 By Investing.com - Investing.com Australia

Nvidia-backed Recursion hurts AI biotechs on mixed data for lead drug - MSN

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Receives $12.67 Consensus Target Price from Analysts - MarketBeat

Recursion Pharmaceuticals executive sells shares worth over $45,000 - Investing.com India

RXRXに似た銘柄